- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06292182
Red Light Ptosis Proof-of-Concept
Can Red Light Lift Droopy Eyelids? An Open-label Proof-of-concept Study
This study tests a new treatment to help with droopy eyelids (ptosis) and eye movement problems (squint) in children and young people with genetically confirmed mitochondrial conditions - using red-light.
We use a torch to shine a red light through the closed eyelid for 3 minutes a day. The study will run for 18 months.
We believe that this treatment could help strengthen the muscle in the eyelid to make it easier to open the eyes, and could also help some children with squint.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Glen Jeffery, PhD
- Phone Number: 020 7608 6800
- Email: g.jeffery@ucl.ac.uk
Study Locations
-
-
-
London, United Kingdom, EC1V 2PD
- Recruiting
- Moorfields Eye Hospital NHS Foundation Trust
-
Contact:
- Annegret H Dahlmann-Noor, PhD
- Phone Number: 020 7253 3411
- Email: annegret.dahlmann-noor@nhs.net
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion: Age 3 to less than 18 years Genetically confirmed diagnosis of primary mitochondrial disease (known pathogenic mutation(s) in mitochondrial or nuclear DNA known to cause primary mitochondrial disease) Ptosis
Exclusion: Genetic diagnosis not consistent with primary mitochondrial disease. No genetic diagnosis Unable to cooperate with light treatment or ophthalmological assessments.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Treatment start at baseline
|
daily application of near-infrared light
|
|
Experimental: Delayed treatment start at 3 months from baseline
|
daily application of near-infrared light
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Palpebral fissure width
Time Frame: 3 months from baseline
|
3 months from baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 160802
- 332942 (Other Identifier: IRAS)
- 58964 (Other Identifier: CPMS)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mitochondrial Diseases
-
Kenneth Myers, MDRecruitingMitochondrial Diseases | Mitochondrial Encephalomyopathy | Mitochondrial Encephalopathy | Mitochondrial DNA Depletion | Mitochondrial Metabolism DisordersCanada
-
Stealth BioTherapeutics Inc.CompletedPrimary Mitochondrial DiseaseUnited States
-
Children's Hospital of PhiladelphiaUnited States Department of DefenseRecruitingMitochondrial Disease | MItochondrial MyopathiesUnited States
-
Stealth BioTherapeutics Inc.TerminatedPrimary Mitochondrial DiseaseUnited States
-
Children's Hospital of PhiladelphiaRecruitingPrimary Mitochondrial DiseaseUnited States
-
Khondrion BVRadboud University Medical CenterCompletedMitochondrial Diseases | Mitochondrial Myopathies | MELAS | Mitochondrial Encephalomyopathies | MIDDNetherlands
-
Newcastle-upon-Tyne Hospitals NHS TrustNewcastle UniversityCompleted
-
BiogenAbbVieCompletedMItochondrial MyopathiesUnited States, Denmark
-
Minovia Therapeutics Ltd.Withdrawn
-
Reneo Pharma LtdTerminatedPrimary Mitochondrial MyopathySpain, Australia, Belgium, Denmark, Canada, United Kingdom, France, Germany, Hungary, Italy, Netherlands, New Zealand
Clinical Trials on Near-infrared light
-
China Medical University HospitalCompletedPhotobiomodulationTaiwan
-
University of MiamiOffice of Naval Research (ONR)Completed
-
Xuanwu Hospital, BeijingNot yet recruitingAlzheimer DiseaseChina
-
Samueli Institute for Information BiologyWilliam Beaumont Army Medical CenterTerminated
-
Sawanya PrutthithawornMahidol UniversityRecruitingDiagnostic Imaging | Tooth, Deciduous | Optical Imaging | Dental Caries (Diagnosis) | Radiographic Image Interpretation, Computer-Assisted | Proximal Dental CariesThailand
-
University of OklahomaRecruitingCognition | Brain Activity | Neurovascular Control | Brain Aging | Neurovascular Coupling Mechanism and Cognitive FunctionUnited States
-
Cerehealth Corp.Colorado Neurological Institute; Tug McGraw FoundationCompletedTBI (Traumatic Brain Injury)
-
Universidad de ValparaisoComisión Nacional de Investigación Científica y TecnológicaUnknownOpen Angle GlaucomaChile
-
Taipei Medical University Shuang Ho HospitalActive, not recruiting
-
Ohio State UniversityCompletedNeoplasms | Bone Diseases | Musculoskeletal Disease | Skull Base Neoplasms | Skull Neoplasms | Bone NeoplasmUnited States